secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000009326-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
---------------------------------------------------------------------

- Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
- Adjusted EBITDA $74.3M (+12.1%); free cash flow $33.8M; operating cash flow $40.1M.
- All three segments posted sales and earnings growth; record Q1 net sales, EBITDA, and net earnings.
- New clinical fMRI study on VitaCholine suggests cognitive health benefits in post-menopausal women.
- CEO cites strong business model resilience; no guidance change despite geopolitical and trade uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000000932626000016/0000009326-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000000932626000016/bcpc-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000009326-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer